In this issue:
PROs help predict survival in early-stage CRC
Obtaining PROs from an Internet-based survivorship tool
Selumetinib: no survival benefit in NSCLC
Oncogenic genetic alterations in adenocarcinoma in the young
Comparative effectiveness of CRC screening strategies
Promising long-term alectinib data in ALK + NSCLC
New guidelines on molecular testing in metastatic CRC
Osimertinib for metastatic EGFR-mutated NSCLC
Uncertainty surrounds cetuximab in metastatic CRC
Cisplatin-etoposide ± bevacizumab in extensive-stage SCLC
Please login below to download this issue (PDF)